$DYN
Dyne Therapeutics, Inc.

2024 Q3 Form 10-Q Financial Statement

#000095017024095527 Filed on August 12, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $12.86M $9.699M
YoY Change 83.18% 27.52%
% of Gross Profit
Research & Development $92.80M $62.26M
YoY Change 67.96% 5.3%
% of Gross Profit
Depreciation & Amortization $400.0K $400.0K
YoY Change 0.0% 0.0%
% of Gross Profit
Operating Expenses $105.7M $71.96M
YoY Change 69.67% 7.83%
Operating Profit -$105.7M -$71.96M
YoY Change 69.67% 7.83%
Interest Expense $9.276M $7.052M
YoY Change 323.56% 219.53%
% of Operating Profit
Other Income/Expense, Net $8.534M $6.860M
YoY Change 313.67% 274.05%
Pretax Income -$97.13M -$65.10M
YoY Change 61.31% 0.31%
Income Tax
% Of Pretax Income
Net Earnings -$97.13M -$65.10M
YoY Change 61.31% 0.31%
Net Earnings / Revenue
Basic Earnings Per Share -$0.96 -$0.70
Diluted Earnings Per Share -$0.96 -$0.70
COMMON SHARES
Basic Shares Outstanding 100.4M 87.38M
Diluted Shares Outstanding

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $723.7M $778.8M
YoY Change 358.54% 274.92%
Cash & Equivalents $532.2M $608.2M
Short-Term Investments $191.5M $170.6M
Other Short-Term Assets $12.72M $13.48M
YoY Change 22.27% 147.83%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $736.4M $792.3M
YoY Change 337.76% 271.68%
LONG-TERM ASSETS
Property, Plant & Equipment $4.896M $5.022M
YoY Change -4.23% -6.29%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.937M $1.927M
YoY Change -15.78% -17.05%
Total Long-Term Assets $32.45M $33.56M
YoY Change -12.35% -12.25%
TOTAL ASSETS
Total Short-Term Assets $736.4M $792.3M
Total Long-Term Assets $32.45M $33.56M
Total Assets $768.8M $825.9M
YoY Change 274.6% 228.49%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.157M $1.889M
YoY Change 73.29% -30.65%
Accrued Expenses $37.10M $27.86M
YoY Change 42.16% 59.25%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $43.26M $29.75M
YoY Change 45.7% 47.14%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $20.04M $20.94M
YoY Change -14.71% -13.92%
Total Long-Term Liabilities $20.04M $20.94M
YoY Change -14.71% -13.92%
TOTAL LIABILITIES
Total Short-Term Liabilities $43.26M $29.75M
Total Long-Term Liabilities $20.04M $20.94M
Total Liabilities $63.30M $50.69M
YoY Change 18.98% 13.8%
SHAREHOLDERS EQUITY
Retained Earnings -$860.4M -$763.3M
YoY Change 52.05% 50.94%
Common Stock $10.00K $10.00K
YoY Change 66.67% 66.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $705.5M $775.2M
YoY Change
Total Liabilities & Shareholders Equity $768.8M $825.9M
YoY Change 274.6% 228.49%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$97.13M -$65.10M
YoY Change 61.31% 0.31%
Depreciation, Depletion And Amortization $400.0K $400.0K
YoY Change 0.0% 0.0%
Cash From Operating Activities -$74.63M -$54.87M
YoY Change 47.49% -1.39%
INVESTING ACTIVITIES
Capital Expenditures $253.0K $857.0K
YoY Change 48.82% 242.8%
Acquisitions
YoY Change
Other Investing Activities -$19.15M $12.03M
YoY Change -247.42% -31.18%
Cash From Investing Activities -$19.40M $11.17M
YoY Change -251.23% -35.16%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 18.01M 379.9M
YoY Change 3815.0% 1425.18%
NET CHANGE
Cash From Operating Activities -74.63M -54.87M
Cash From Investing Activities -19.40M 11.17M
Cash From Financing Activities 18.01M 379.9M
Net Change In Cash -76.02M 336.2M
YoY Change 103.76% -2589.4%
FREE CASH FLOW
Cash From Operating Activities -$74.63M -$54.87M
Capital Expenditures $253.0K $857.0K
Free Cash Flow -$74.88M -$55.72M
YoY Change 47.49% -0.3%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001818794
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39509
dei Entity Registrant Name
EntityRegistrantName
Dyne Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
36-4883909
dei Entity Address Address Line1
EntityAddressAddressLine1
1560 Trapelo Road
dei Entity Address City Or Town
EntityAddressCityOrTown
Waltham
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02451
dei City Area Code
CityAreaCode
781
dei Local Phone Number
LocalPhoneNumber
786-8230
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
DYN
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
100400798
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
608196000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
121626000
CY2024Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
170642000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
1474000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
13482000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6275000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
792320000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
129375000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5022000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4780000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
26615000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
28612000
CY2024Q2 dyn Restricted Cash And Other Assets Noncurrent
RestrictedCashAndOtherAssetsNoncurrent
1927000
CY2023Q4 dyn Restricted Cash And Other Assets Noncurrent
RestrictedCashAndOtherAssetsNoncurrent
2315000
CY2024Q2 us-gaap Assets
Assets
825884000
CY2023Q4 us-gaap Assets
Assets
165082000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1889000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
22936000
CY2024Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
23085000
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
23439000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4779000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4720000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
29753000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
51095000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
20938000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
22695000
CY2024Q2 us-gaap Liabilities
Liabilities
50691000
CY2023Q4 us-gaap Liabilities
Liabilities
73790000
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
100119518
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
100119518
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
61468743
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
61468743
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
10000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
6000
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1538684000
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
723796000
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-240000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
0
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-763261000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-632510000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
775193000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
91292000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
825884000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
165082000
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
62263000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
59130000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
106802000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
96667000
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9699000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7606000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
34317000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15533000
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
71962000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
66736000
us-gaap Operating Expenses
OperatingExpenses
141119000
us-gaap Operating Expenses
OperatingExpenses
112200000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-71962000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-66736000
us-gaap Operating Income Loss
OperatingIncomeLoss
-141119000
us-gaap Operating Income Loss
OperatingIncomeLoss
-112200000
CY2024Q2 us-gaap Interest Income Other
InterestIncomeOther
7052000
CY2023Q2 us-gaap Interest Income Other
InterestIncomeOther
2207000
us-gaap Interest Income Other
InterestIncomeOther
10054000
us-gaap Interest Income Other
InterestIncomeOther
3700000
CY2024Q2 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-192000
CY2023Q2 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-373000
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
314000
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-589000
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
6860000
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1834000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
10368000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3111000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-65102000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-64902000
us-gaap Net Income Loss
NetIncomeLoss
-130751000
us-gaap Net Income Loss
NetIncomeLoss
-109089000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.7
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.7
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.08
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.08
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.51
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.51
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.88
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.88
CY2024Q2 us-gaap Weighted Average Limited Partnership Units Outstanding Diluted
WeightedAverageLimitedPartnershipUnitsOutstandingDiluted
92507815
CY2024Q2 us-gaap Weighted Average Limited Partnership Units Outstanding
WeightedAverageLimitedPartnershipUnitsOutstanding
92507815
CY2023Q2 us-gaap Weighted Average Limited Partnership Units Outstanding Diluted
WeightedAverageLimitedPartnershipUnitsOutstandingDiluted
59835087
CY2023Q2 us-gaap Weighted Average Limited Partnership Units Outstanding
WeightedAverageLimitedPartnershipUnitsOutstanding
59835087
us-gaap Weighted Average Limited Partnership Units Outstanding
WeightedAverageLimitedPartnershipUnitsOutstanding
86777150
us-gaap Weighted Average Limited Partnership Units Outstanding Diluted
WeightedAverageLimitedPartnershipUnitsOutstandingDiluted
86777150
us-gaap Weighted Average Limited Partnership Units Outstanding
WeightedAverageLimitedPartnershipUnitsOutstanding
58090142
us-gaap Weighted Average Limited Partnership Units Outstanding Diluted
WeightedAverageLimitedPartnershipUnitsOutstandingDiluted
58090142
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-65102000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-64902000
us-gaap Net Income Loss
NetIncomeLoss
-130751000
us-gaap Net Income Loss
NetIncomeLoss
-109089000
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-108000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
147000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-240000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
515000
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-65210000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-64755000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-130991000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-108574000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
91292000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
10916000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
19906000
CY2024Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-132000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-65649000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
478055000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4283000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6736000
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-108000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-65102000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
775193000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
252364000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
587000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4617000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
368000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-44187000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
241935000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
764000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4749000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
147000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-64902000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
206877000
us-gaap Profit Loss
ProfitLoss
-130751000
us-gaap Profit Loss
ProfitLoss
-109089000
us-gaap Share Based Compensation
ShareBasedCompensation
26642000
us-gaap Share Based Compensation
ShareBasedCompensation
9366000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
785000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
843000
dyn Non Cash Lease Expense
NonCashLeaseExpense
298000
dyn Non Cash Lease Expense
NonCashLeaseExpense
454000
dyn Amortization Accretion Of Premium Discount On Marketable Securities
AmortizationAccretionOfPremiumDiscountOnMarketableSecurities
-1792000
dyn Amortization Accretion Of Premium Discount On Marketable Securities
AmortizationAccretionOfPremiumDiscountOnMarketableSecurities
-543000
dyn Loss On Sale Of Marketable Securities
LossOnSaleOfMarketableSecurities
0
dyn Loss On Sale Of Marketable Securities
LossOnSaleOfMarketableSecurities
23000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
2000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-118000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
7207000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-4175000
us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
-21378000
us-gaap Increase Decrease In Accounts Payable And Other Operating Liabilities
IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities
-7897000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-133405000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-102550000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1048000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
480000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
207691000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
34684000
dyn Maturities Of Marketable Securities
MaturitiesOfMarketableSecurities
40076000
dyn Maturities Of Marketable Securities
MaturitiesOfMarketableSecurities
77629000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
1829000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-168663000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
44294000
dyn Proceeds From Issuance Follow On Public Offering
ProceedsFromIssuanceFollowOnPublicOffering
675180000
dyn Proceeds From Issuance Follow On Public Offering
ProceedsFromIssuanceFollowOnPublicOffering
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
97871000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
52370000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
15199000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1351000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
788250000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
53721000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
486182000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4535000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
123941000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
174466000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
610123000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
169931000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
10000
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2017-12-01
us-gaap Dividends Common Stock Paidinkind
DividendsCommonStockPaidinkind
11192116000
us-gaap Dividends Common Stock Paidinkind
DividendsCommonStockPaidinkind
10717818000
CY2023Q4 us-gaap Change In Accounting Principle Accounting Standards Update Immaterial Effect
ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect
true
CY2023Q4 us-gaap Change In Accounting Principle Accounting Standards Update Adoption Date
ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate
2024-12-31
CY2023Q4 us-gaap Change In Accounting Principle Accounting Standards Update Adopted
ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted
true
dyn Cash And Cash Equivalents Maturity Period
CashAndCashEquivalentsMaturityPeriod
P90D
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
608196000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
121626000
CY2024Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1927000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
2315000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
610123000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
123941000
CY2024Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
170872000
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
30000
CY2024Q2 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
260000
CY2024Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
170642000
CY2023Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
1474000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
0
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
0
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
1474000
CY2024Q2 dyn Fair Value Assets Transfers Amount
FairValueAssetsTransfersAmount
0
CY2023Q4 dyn Fair Value Assets Transfers Amount
FairValueAssetsTransfersAmount
0
CY2024Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
155058000
CY2024Q2 dyn Available For Sale Debt Securities Maturity After Year One Through Two Years Fair Value
AvailableForSaleDebtSecuritiesMaturityAfterYearOneThroughTwoYearsFairValue
15584000
CY2024Q2 dyn Available For Sale Debt Securities Maturity After Year Two Years Fair Value
AvailableForSaleDebtSecuritiesMaturityAfterYearTwoYearsFairValue
0
CY2024Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
170642000
CY2024Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
11094000
CY2023Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
10068000
CY2024Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6072000
CY2023Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5288000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5022000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4780000
CY2024Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
400000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
800000
CY2023Q2 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
400000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
800000
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8178000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
10498000
CY2024Q2 dyn Accrued Consulting Services Current
AccruedConsultingServicesCurrent
1098000
CY2023Q4 dyn Accrued Consulting Services Current
AccruedConsultingServicesCurrent
423000
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1094000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
397000
CY2024Q2 dyn Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
12715000
CY2023Q4 dyn Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
12121000
CY2024Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
23085000
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
23439000
dyn Number Of Directors
NumberOfDirectors
2
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.66
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.67
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0398
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0465
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0342
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0422
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9914719
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.48
CY2023 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y8M12D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
38732000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1215868
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
26.9
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
2423695
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
6.27
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
343612
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
12.45
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8363280
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
178018000
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4471976
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
12.03
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y9M18D
CY2024Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
104022000
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
8363280
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
14
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
178018000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
45400000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
7000000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
17.04
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.93
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6736000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4749000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
26642000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9366000
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-095527-index-headers.html Edgar Link pending
0000950170-24-095527-index.html Edgar Link pending
0000950170-24-095527.txt Edgar Link pending
0000950170-24-095527-xbrl.zip Edgar Link pending
dyn-20240630.htm Edgar Link pending
dyn-20240630.xsd Edgar Link pending
dyn-ex31_1.htm Edgar Link pending
dyn-ex31_2.htm Edgar Link pending
dyn-ex32_1.htm Edgar Link pending
dyn-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
dyn-20240630_htm.xml Edgar Link completed
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending